The European Commission said on Thursday that it signed a third contract with pharmaceutical companies BioNTech SE and Pfizer Inc for an additional 1.8 billion doses of the coronavirus vaccine.

The contract reserves the doses on behalf of all European Union member states, between end 2021 to 2023, the statement added. The contract requires that the vaccine production is based in the EU and that essential components are sourced from the EU.